Zacks Investment Research downgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a sell rating in a report released on Saturday morning, Zacks.com reports.

According to Zacks, “Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company’s lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in MontrĂ©al, Canada. “

MIST has been the topic of a number of other reports. ValuEngine upgraded shares of Milestone Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, October 1st. Cowen reiterated a buy rating and issued a $32.00 price target on shares of Milestone Pharmaceuticals in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Milestone Pharmaceuticals has a consensus rating of Buy and an average price target of $30.10.

NASDAQ MIST traded up $0.42 on Friday, reaching $18.00. The company had a trading volume of 388 shares, compared to its average volume of 3,874. The stock’s 50 day moving average is $18.95. Milestone Pharmaceuticals has a 12 month low of $15.09 and a 12 month high of $27.95.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Wednesday, November 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). As a group, equities analysts anticipate that Milestone Pharmaceuticals will post -3.29 earnings per share for the current fiscal year.

In other Milestone Pharmaceuticals news, major shareholder Stonepine Capital, L.P. bought 100,000 shares of Milestone Pharmaceuticals stock in a transaction dated Friday, October 11th. The shares were purchased at an average cost of $0.63 per share, for a total transaction of $63,000.00. Also, major shareholder Rtw Investments, Lp bought 5,487 shares of Milestone Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average price of $18.95 per share, for a total transaction of $103,978.65. Over the last quarter, insiders acquired 113,637 shares of company stock worth $311,967.

Several institutional investors have recently bought and sold shares of MIST. Landscape Capital Management L.L.C. bought a new stake in shares of Milestone Pharmaceuticals in the 2nd quarter worth about $459,000. Tower Research Capital LLC TRC bought a new stake in shares of Milestone Pharmaceuticals in the 2nd quarter worth about $51,000. VHCP Management II LLC bought a new stake in shares of Milestone Pharmaceuticals in the 2nd quarter worth about $4,033,000. VHCP Management III LLC bought a new stake in shares of Milestone Pharmaceuticals in the 2nd quarter worth about $56,106,000. Finally, Farallon Capital Management LLC bought a new stake in shares of Milestone Pharmaceuticals in the 2nd quarter worth about $6,788,000. Hedge funds and other institutional investors own 53.33% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Featured Article: How Buying a Call Option Works

Get a free copy of the Zacks research report on Milestone Pharmaceuticals (MIST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.